The Body Covers: The 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy
Safety of Saquinavir Soft Gelatin Capsule (SQV-SGC) with Other Antiviral Agents
September 28 - October 1, 1997 A note from TheBody.com: The field of medicine is constantly evolving. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! Abstract I -90A larger trial of the safety and tolerability of the soft gel saquinavir involving 442 patients in an open label study. The patients added SQV-SGC to any pre-existing medications, or preferably, could change the other medications at the same time. After 48 weeks, 70% were still on the study.Diarrhea occurred in 20% (not much detail on severity), nausea in 11%, heartburn in 8% and flatulence in 8%. Mild to moderate increases in liver enzymes were seen in about 1%. Taken together with other studies, these two studies suggest that saquinavir in the new formulation is a highly active protease inhibitor. With the increased blood levels and efficacy seem to come some more side effects, but these seem to be mild, manageable (so far) and on a par with other protease inhibitors. It is important to realize that, like the other PI's, using the new saquinavir formulation carelessly will lead to resistance and a once resistance develops to one PI, there is broad cross resistance. A note from TheBody.com: The field of medicine is constantly evolving. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!
This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.
|